Healthcare and energy stocks both advanced 0.39% at midday Wednesday. The US Federal Reserve is expected to keep interest rates steady in its monetary policy statement on Wednesday.
Imugene (ASX:IMU) obtained fast-track designation from the US Food and Drug Administration for azer-cel, a potential treatment for relapsed or refractory diffuse large B-cell lymphoma. Azer-cel is in phase 1b clinical trial.
On the flip side, the utilities sector struggled, falling 0.95%. The S&P 500, Dow Jones, and Nasdaq composite indices fell in overnight trading and Australian stocks followed them lower.
Contact Energy (ASX:CEN, NZE:CEN) said its consent application for the proposed Southland Wind Farm project in New Zealand was denied by the Expert Consenting Panel convened under the COVID-19 Recovery Act of 2020.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.